Metabolism-based Targeting of MYC Via MPC-SOD2 Axis-mediated Oxidation Promotes Cellular Differentiation in Group 3 Medulloblastoma
Overview
Authors
Affiliations
Group 3 medulloblastoma (G3 MB) carries the worst prognosis of all MB subgroups. MYC oncoprotein is elevated in G3 MB tumors; however, the mechanisms that support MYC abundance remain unclear. Using metabolic and mechanistic profiling, we pinpoint a role for mitochondrial metabolism in regulating MYC. Complex-I inhibition decreases MYC abundance in G3 MB, attenuates the expression of MYC-downstream targets, induces differentiation, and prolongs male animal survival. Mechanistically, complex-I inhibition increases inactivating acetylation of antioxidant enzyme SOD2 at K68 and K122, triggering the accumulation of mitochondrial reactive oxygen species that promotes MYC oxidation and degradation in a mitochondrial pyruvate carrier (MPC)-dependent manner. MPC inhibition blocks the acetylation of SOD2 and oxidation of MYC, restoring MYC abundance and self-renewal capacity in G3 MB cells following complex-I inhibition. Identification of this MPC-SOD2 signaling axis reveals a role for metabolism in regulating MYC protein abundance that has clinical implications for treating G3 MB.
Fu H, Zhang Y, Duan Y, Zhang X, Yao J, Yang D iScience. 2025; 28(2):111553.
PMID: 39898027 PMC: 11787496. DOI: 10.1016/j.isci.2024.111553.
Mechanisms of metabolism-coupled protein modifications.
Zhang B, Schroeder F Nat Chem Biol. 2025; .
PMID: 39775169 DOI: 10.1038/s41589-024-01805-z.
Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules.
Bibbo F, Asadzadeh F, Boccia A, Sorice C, Bianco O, Sacca C Int J Mol Sci. 2024; 25(7).
PMID: 38612726 PMC: 11011515. DOI: 10.3390/ijms25073917.